{"nctId":"NCT01137812","briefTitle":"The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)","startDateStruct":{"date":"2010-07"},"conditions":["Diabetes Mellitus, Type 2"],"count":756,"armGroups":[{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin 300 mg","Drug: Metformin","Drug: Sulphonylurea"]},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sitagliptin 100 mg","Drug: Metformin","Drug: Sulphonylurea"]}],"interventions":[{"name":"Sitagliptin 100 mg","otherNames":[]},{"name":"Canagliflozin 300 mg","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Sulphonylurea","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea\n* Patients in the study must have a HbA1c between \\>=7 and \\<=10.5% and a fasting plasma glucose (FPG) \\<300 mg/dL (16.7 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* or a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":"0.048"},{"groupId":"OG001","value":"-0.66","spread":"0.049"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 52","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 52 in each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.9","spread":"2.201"},{"groupId":"OG001","value":"-5.85","spread":"2.232"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"0.2"},{"groupId":"OG001","value":"0.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"0.656"},{"groupId":"OG001","value":"0.85","spread":"0.666"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 52","description":"The table below shows the mean percent change in triglycerides from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"2.8"},{"groupId":"OG001","value":"11.9","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52","description":"The table below shows the mean percent change in HDL-C from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"0.9"},{"groupId":"OG001","value":"0.6","spread":"0.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":377},"commonTop":["Hypoglycaemia","Nasopharyngitis","Headache","Upper respiratory tract infection","Diarrhoea"]}}}